ABL1 is altered in 3.33% of acute leukemia of ambiguous lineage patients [2].

ABL1 is an inclusion eligibility criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 0 are open and 1 is closed. Of the trial that contains ABL1 status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 2 (0 open) [3].

AFF1 is an inclusion eligibility criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 0 are open and 1 is closed. Of the trial that contains AFF1 status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 2 (0 open) [3].

BCR is altered in 3.12% of acute leukemia of ambiguous lineage patients [2].

BCR is an inclusion eligibility criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 0 are open and 1 is closed. Of the trial that contains BCR status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 2 (0 open) [3].

DEK is an inclusion eligibility criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 0 are open and 1 is closed. Of the trial that contains DEK status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 2 (0 open) [3].

ELL is an inclusion eligibility criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 0 are open and 1 is closed. Of the trial that contains ELL status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 2 (0 open) [3].

FLT3 is altered in 5.0% of acute leukemia of ambiguous lineage patients [2].

FLT3 is an inclusion eligibility criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 2 (0 open) [3].

KMT2A is altered in 2.04% of acute leukemia of ambiguous lineage patients [2].

KMT2A is an inclusion eligibility criterion in 2 clinical trials for acute leukemia of ambiguous lineage, of which 1 is open and 1 is closed. Of the trials that contain KMT2A status and acute leukemia of ambiguous lineage as inclusion criteria, 2 are phase 2 (1 open) [3].

MDM2 is an inclusion eligibility criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 1 (1 open) [3].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 1 (1 open) [3].

MECOM is an inclusion eligibility criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 0 are open and 1 is closed. Of the trial that contains MECOM status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 2 (0 open) [3].

MLLT1 is an inclusion eligibility criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 0 are open and 1 is closed. Of the trial that contains MLLT1 status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 2 (0 open) [3].

MLLT10 is an inclusion eligibility criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 0 are open and 1 is closed. Of the trial that contains MLLT10 status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 2 (0 open) [3].

MLLT3 is an inclusion eligibility criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 0 are open and 1 is closed. Of the trial that contains MLLT3 status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 2 (0 open) [3].

MLLT4 is an inclusion eligibility criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 0 are open and 1 is closed. Of the trial that contains MLLT4 status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 2 (0 open) [3].

NRIP3 is an inclusion eligibility criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 0 are open and 1 is closed. Of the trial that contains NRIP3 status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 2 (0 open) [3].

NUP214 is an inclusion eligibility criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 0 are open and 1 is closed. Of the trial that contains NUP214 status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 2 (0 open) [3].

PBX1 is an inclusion eligibility criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 0 are open and 1 is closed. Of the trial that contains PBX1 status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 2 (0 open) [3].

PPM1D is an inclusion eligibility criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 1 is open and 0 are closed. Of the trial that contains PPM1D status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 1 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 0 are open and 1 is closed. Of the trial that contains RPN1 status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 2 (0 open) [3].

SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 1 (1 open) [3].

SMARCB1 is an inclusion eligibility criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 1 (1 open) [3].

TCF3 is an inclusion eligibility criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 0 are open and 1 is closed. Of the trial that contains TCF3 status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 2 (0 open) [3].

TET2 is altered in 11.86% of acute leukemia of ambiguous lineage patients [2].

TET2 is an inclusion eligibility criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 1 is open and 0 are closed. Of the trial that contains TET2 status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 1 (1 open) [3].

TP53 is altered in 13.33% of acute leukemia of ambiguous lineage patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 2 (0 open) [3].